Overview IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer Status: Not yet recruiting Trial end date: 2024-06-01 Target enrollment: Participant gender: Summary This research study is designed to establish whether the combination of IBI310 & Sintilimab has efficacy in patients with advanced BTC Phase: Phase 1/Phase 2 Details Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.